Search DubaiPRNetwork.com

Home >> Healthcare & Medicine

Takeda announces results of pioneering Ulcerative Colitis study

Monday, March 11, 2019/ Editor -  

Share

Home >> Healthcare & Medicine
  • The pharmaceutical leader conducted an industry-first head-to-head study of two biologic therapies commonly used to treat the illness: vedolizumab and adalimumab
  • Vedolizumab was found to be superior in achieving clinical remission and mucosal healing at week 52
  • Study focused on patients with moderately to severely active ulcerative colitis  
Dubai, UAE, March 11, 2019:   Global biopharmaceutical company Takeda today announced the results of its pioneering VARSITY study into the effectiveness of two common therapies used to treat Ulcerative Colitis. Shared at the 14th Congress of the European Crohn’s and Colitis Organization (ECCO) in Copenhagen Denmark, the findings showed that the use of vedolizumab – a gut-selective biologic treatment, was more effective overall at tackling the illness when compared to adalimumab– a common anti-tumor therapy.
 
Specifically, the study found that by week 52 of treatment among patients with moderate to severely active ulcerative colitis, 31.3 percent of those receiving vedolizumab intravenously experienced clinical remission*, compared to 22.5 percent of patients receiving adalimumab via injection at week 52. In addition, 39.7 percent of patients treated with vedolizumab recorded mucosal healing** - a slowing of the disease’s progression, compared to 27.7 percent of those receiving adalimumab.
 
A non-statistically significant difference in favor of adalimumab was seen among patients who stopped taking oral corticosteroids - steroid hormones that are usually produced in the adrenal gland and were in clinical remission*** at week 52. Meanwhile, although the study was not conducted to compare the safety of the two treatments, patients treated with vedolizumab had a lower rate (62.7 percent) of adverse effects over 52 weeks compared to patients receiving adalimumab treatment (69.2 percent). Those treated with vedolizumab recorded a lower rate of infection (33.5 percent) compared to patients treated with adalimumab (43.5 percent). The rate of serious adverse events was also lower in vedolizumab-treated patients than adalimumab (11.0% vs. 13.7% respectively).
 
“The VARSITY study addresses critical questions concerning the selection of biologic therapy in ulcerative colitis. The goal of treatment of this disease is to achieve clinical remission and mucosal healing, and these results clearly highlight the benefits seen with vedolizumab versus adalimumab towards these important outcomes.” said Dr. Bruce E. Sands, primary investigator of the VARSITY study and Chief of both the Dr. Henry D. Janowitz Division of
Gastroenterology at Mount Sinai Hospital, and the Icahn School of Medicine at Mount Sinai in New York.
 
Jeff Bornstein, M.D., Executive Medical Director, Takeda added, “The study gives physicians invaluable knowledge towards treatment decisions when starting biologic therapy. This is also the first time we have seen a direct comparison between two medicines with distinct modes of action in ulcerative colitis. This is an exciting time in the landscape of ulcerative colitis treatment, as head-to-head clinical data has not previously been available to guide treatment decisions around biologic therapies.”
 
The VARSITY study comprised a random selection of 769 patients, all of whom had shown an inadequate response with, loss of response to, or intolerance to corticosteroids, immunomodulators, or one TNFα-antagonist other than adalimumab before being enrolled. 
 
Patients were randomly placed into one of two treatment groups - vedolizumab IV and placebo SC or adalimumab SC and placebo IV. Patients in the vedolizumab group were administered 300 mg of vedolizumab IV at weeks 0, 2, 6 and every 8 weeks after until week 46, along with placebo SC at week 0 and every 2 weeks until week 50. The adalimumab group were administered 160 mg of adalimumab SC at week 0, 80 mg at week 2 and 40 mg every 2 weeks until week 50, along with placebo IV at weeks 0, 2, 6 and every 8 weeks thereafter until week 46. Dose escalation was not permitted in either treatment arm during the study.1, 

Previous in Healthcare & Medicine

Next in Healthcare & Medicine


Home >> Healthcare & Medicine Section

Latest Press Release

The American Community School of Abu Dhabi Awards the Haitham Zamzam Al Hammadi ...

du Offers Seamless Telco Experience with UAE-First Linksys Training Initiative

61 percent of employees believe sustainability is mandatory for modern businesse ...

Longchamp & Kendall Jenner Celebrate the Launch of the Longchamp Lgp Collection ...

Embrace the Spirit of the Holy Month of Ramadan at Yas Mall, The Mall at World T ...

Seamless Customer Experience at Airports - Genetec

EEG Environemtnal Drawing Competition 2019

Jaguar Land Rover's Fiona Pargeter Recognised as Inaugural ‘woman of Worth' 2018

Jafza to Waive Aed 35 Million in Fines

Ramadan Promotion: 300% Bonus of the recharge value from Etisalat to share the s ...

Sharjah realty transactions hit AED5.2b in Q-1

Um Al Quwain Police and Pure Gold Jewellers unite prisoners with their families ...

Western Furniture announces Best Buy sale during Ramadan

Future Network Awards 2019 Awards Schneider Electric and NPCC under the category ...

The All-new Flying Spur: the Luxury Grand Touring Sedan

Travel Essentials Guide

New research from NYU Abu Dhabi discovers growing teleconnection between Atlanti ...

Marina Mall Abu Dhabi supports Make A Wish Foundation UAE with special Ramadan B ...

Salvatore Ferragamo Features Leather Sunglasses In the Spring/summer 2019 Adver ...

Michael Kors Co-hosts the 10th Anniversary of the Annual Filmmakers Dinner